Hepatocellular carcinoma (HCC) is the most common primary liver cancer and a major cause of cancer-related deaths worldwide. Assessing the risk of recurrence after HCC treatment is crucial for determining appropriate surveillance and management strategies. The platelet-to-lymphocyte ratio (PLR) has emerged as a potential biomarker for prognosis in several types of cancer. However, most of the studies on PLR in liver cancer have been carried out in Caucasian and Oriental populations, and its prognostic value in in the Hispanic population remains unclear. This is a retrospective study that analyzed the prognostic value of PLR in Hispanic (Mexican) patients diagnosed with HCC, analyzing with overall survival (OS), tumor size and BCLC stage. The patients were divided into two groups based on PLR (PLR ≥125 and PLR <125). The clinical characteristics and OS were collected, using kaplan-Meier method. The results showed that patients with PLR ≥125 had significantly shorter median OS compared to those with PLR <125 (4.5 months vs 8.2 months). Patients with shorter tumor sizes had a lower PLR mean (1 to 3 nodules ≤3cm and a PLR= 121.04) compared to those with larger tumors (tumor covering more than 60% of the liver and a mean PLR of 216.8), Moreover, we found that patients in stages B and D had higher PLR and worse survival (mean PLR value of 191.37 and an OS of 8.76 months and a mean PLR value of 208.41and an OS of 4.8 months respectively) compared to stages A and C patients. These findings suggest that a higher PLR (PLR ≥125) may be indicative of a worse prognosis in HCC Hispanic (Mexican) patients. Further investigation and validation of PLR as a prognostic marker in larger Hispanic cohorts is warranted.